48
Participants
Start Date
October 22, 2020
Primary Completion Date
October 26, 2022
Study Completion Date
June 10, 2023
Q4W GMA301 IV injections (300 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Q4W GMA301 IV injections (600 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Q4W GMA301 IV injections (1000 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Q4W GMA301 IV injections (1800 mg)
Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Q4W placebo IV injections
Placebo is indistinguishable from GMA301.
RECRUITING
Brigham and Women's Hospital, Boston
RECRUITING
Peking Union Medical College Hospital - Dongcheng District, Beijing
RECRUITING
Xiangya Hospital, Central South University, Changsha
RECRUITING
The First Affiliated Hospital of Chongqing Medical University, Chongqing
RECRUITING
Guangdong General Hospital, Guangzhou
RECRUITING
Shanghai Pulmonary Hospital, Shanghai
RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Lead Sponsor
Gmax Biopharm LLC.
INDUSTRY